Kidney Health Gateway
Back to all trials
Currently Enrolling
Interventional

LNP023 for IgAN Patients

An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Brief Description

The purpose of this study is to establish clinical proof-of-concept of effectiveness and to evaluate dose responses of the study drug in patients with IgAN.

Study Coordinator

Novartis Pharmaceuticals

Email Phone 1-888-669-6682
Site Name

Novartis Investigative Site

Sponsor

Novartis Pharmaceuticals

Study Drug

LNP023

Estimated enrollment

48

Estimated end date

April, 2019

If there is not a site for a clinical trial nearby, you can ask the study team about the possibility of travel reimbursements (i.e., paying you back for your travel costs). Alternatively, you can ask about the possibility of participating from home.
Find other locations for this trial:
Currently Enrolling
Interventional

LNP023 for IgAN Patients

An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Brief Description

The purpose of this study is to establish clinical proof-of-concept of effectiveness and to evaluate dose responses of the study drug in patients with IgAN.

Trial for people with

IgA Nephropathy

Study Goal

To determine if patients taking the study drug experience a change in their urine protein to creatinine concentration.

What is involved for the Patient?

Patients will be involved in the trial for about 3 months, and will need to do regular labwork.

About the drug or intervention

LNP023 is a new compound that is meant to stop inflammation in the body.

Find other locations for this trial:
Bangkok
Frequently Asked Questions

Nephrotic Syndrome is not a disease itself, but rather a group of signs and symptoms that result from damage in the part of the kidney that filters blood (glomeruli).

Common symptoms include:

  • Foamy urine (called proteinuria) caused by protein “spilling” into the urine
  • Severe swelling in parts of the body, most noticeably around the eyes, hands, feet, and abdomen (called edema)
  • Weight gain due to a buildup of extra fluid
  • Fatigue
  • Loss of appetite
  • Low levels of protein in the blood (hypoalbuminemia)
  • Higher than normal fat and cholesterol levels in the blood (hyperlipidemia)

Nephrotic Syndrome can typically be diagnosed with a urine test.

Nephrotic Syndrome can be “primary” or “secondary” in nature.

Diseases that affect only the kidneys are called primary causes of Nephrotic Syndrome. Doctors often call these diseases “idiopathic,” which means that they arise from an unknown cause. Some of these diseases include:

  • Minimal Change Disease (MCD) – most common in children
  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous Nephropathy (MN) – most common in adults
  • IgA Nephropathy (IgAN)

Secondary Nephrotic Syndrome is caused by an underlying, systemic condition like diabetes, lupus, HIV, and others.

The Kidney Health Gateway is a website owned and operated by NephCure Kidney International. The purpose of this website is to help patients with rare forms of primary Nephrotic Syndrome get connected to expert care and cutting-edge treatment options. By answering a few questions about you or your loved one’s condition, we can provide you with a list of clinical trials and/or expert doctors in your area.

If you have additional questions, please visit NephCure.org or email Info@NephCure.org.

 

See other frequently asked questions